ONCOLYTICS BIOTECH INC 8-K

What Happened On May 22, 2026, Oncolytics Biotech Inc. (ONCY) filed an 8-K to announce a press release (attached as Exhibit 99.1) that certain translational data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The data come from the GOBLET and AWARE-1 studies and describe pelareorep’s mechanism of action and its effect on activation of the innate and adaptive immune system. The filing is signed by Kirk Look, Chief Financial Officer, dated May 22, 2026.

Key Details

• Filing date: May 22, 2026 (Form 8-K, Item 8.01 Other Events).
• Data source: Translational results from the GOBLET and AWARE-1 clinical studies.
• Topic: Pelareorep’s mechanism of action and activation of innate and adaptive immunity.
• Press release included as Exhibit 99.1 to the 8-K.

Why It Matters This 8-K alerts investors that Oncolytics will publicly present biology-focused data on pelareorep at a major oncology meeting (ASCO), which could inform the scientific and clinical community’s view of the drug candidate’s immune activity. While the filing does not include clinical outcome or financial results, the translational data may affect perceptions of ONCY’s development progress and potential future milestones tied to pelareorep.